Dayton Misfeldt has served as a member of our board of directors since April 2009 and was appointed Interim Chief Executive Officer in January 2018. Mr. Misfeldt is a Managing Director at Bay City Capital LLC and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at Life Science Economics. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego.